Scorpius Holdings, Inc.

As of November 13, 2017, Scorpius Holdings, Inc. is classified as risky due to significant financial deterioration, overvaluation indicated by a Price to Book Value of 0.08, an EV to EBITDA of -0.65, a Return on Equity of -530.53%, and a year-to-date stock return of -99.61% compared to the S&P 500's 12.22%.

As of November 13, 2017, Scorpius Holdings, Inc. is considered overvalued and risky due to severe financial distress, reflected in a price-to-book value of 0.08, an EV to EBITDA ratio of -0.65, and negative returns on capital and equity, alongside a year-to-date stock performance decline of 87.03% compared to the S&P 500's 2.44% gain.

As of May 8, 2025, Scorpius Holdings, Inc. shows a mildly bearish trend due to daily moving averages indicating bearish momentum, while mixed signals from MACD, RSI, and Bollinger Bands suggest a cautious approach.

As of March 2022, the management team of Scorpius Holdings, Inc. includes Mr. Jeffrey Wolf as Chairman, President, and CEO, Dr. John Prendergast as Lead Independent Director, and Dr. John Monahan and Mr. Edward Smith as Independent Directors.

Scorpius Holdings, Inc. is a development-stage immuno-oncology company focused on creating allogeneic, off-the-shelf cellular therapeutic vaccines for cancer treatment. It has a market cap of $0.50 million, with recent net sales of $1 million and a net loss of $10 million.

As of Jun 18, Scorpius Holdings, Inc. has a market capitalization of 0.50 million, with net sales of 6.24 million and a net profit of -34.33 million over the last four quarters. The company has shareholder's funds of 6.30 million and total assets of 39.18 million as of Dec 24.